R eactive arthritis (ReA) is a non-purulent joint inflammation which can be triggered by bacterial infections in the urogenital tract or in the gut, including the enteric pathogens Yersinia pseudotuberculosis and Yersinia enterocolitica. Infections caused by Y pseudotuberculosis are much less common than those caused by Y enterocolitica 1 2 and reports of outbreaks are rare. 3 Y enterocolitica is a well established trigger of ReA. 4 Several case reports of ReA triggered by Y pseudotuberculosis have been published, mostly from European countries, including Finland, France, Netherlands, and the United Kingdom, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] but also from Canada. 18 In only two outbreaks caused by Y pseudotuberculosis, musculoskeletal complications have been followed up in larger case series. 2 3 An outbreak of Y pseudotuberculosis serotype O:3 occurred recently in Finland enabling evaluation of the frequency and characteristics of reactive musculoskeletal complications in association with such an infection and confirming the severity of these complications during such an infection.
PATIENTS AND METHODS
The outbreak A widespread food-borne outbreak of Y pseudotuberculosis infections occurred in Finland. From 15 October to 6 November 1998, a total of 47 cases with culture confirmed Y pseudotuberculosis serotype O:3 infection were identified nation wide through laboratory based surveillance. The patients ranged in age from 2 to 77 years (median 19); 25 (53%) were women and 19 (40%) were aged <15 years. Clinical microbiology laboratories forwarded bacterial isolates to the Laboratory of Enteric Pathogens at the National Public Health Institute for serotyping. Residents of two health districts in southern Finland accounted for 40 (85%) of the patients. Of these, 38 were enrolled in a population based case-control study conducted by the Department of Infectious Disease Epidemiology. The investigation implicated domestic iceberg lettuce as the vehicle for Y pseudotuberculosis infection. 19 The survey on musculoskeletal symptoms The questionnaire on musculoskeletal symptoms was sent to the 38 subjects who were enrolled in the case-control study to investigate the cause of the outbreak about four months after the onset of gastrointestinal symptoms of Y pseudotuberculosis infection. The questionnaire was slightly modified from that used in our earlier studies on the association of ReA with salmonella outbreaks. 20 21 It included questions about the presence, severity, and duration of diarrhoea, the presence and duration of concomitant symptoms of infection, such as abdominal pain, fever, eye, urinary and skin symptoms, painful or swollen joints, pain in tendon insertions, back pain, onset and duration of these symptoms, previous joint symptoms, eventual visits to a doctor or to a hospital because of these symptoms, and drug treatment. The questionnaire also included a graphic representation of the body on which the subject was asked to mark swollen or painful joints and tendons.
Diagnostic criteria
ReA was defined as development of synovitis (either swelling or limitation of joint movement, and pain) in a previously asymptomatic joint within the first four weeks after culture confirmed infection with Y pseudotuberculosis O:3. In addition, other reactive musculoskeletal complications such as signs or symptoms of inflammatory sacroiliitis, tendinitis, bursitis, or enthesopathy could be present. Each affected joint in fingers and toes was counted individually. Tendinitis, enthesopathy, and bursitis were regarded as reactive if they occurred within the first four weeks after the infection.
Patients who reported symptoms suggestive of ReA or other reactive musculoskeletal problem were interviewed by telephone (TH) to assess whether the arthritis or other musculoskeletal symptoms were associated with infection. If the subject had visited a doctor because of recent joint complaints, the patient charts were reviewed.
The ethics committee of the Helsinki University Central Hospital and of the National Public Health Institute, Helsinki, approved the study.
Statistical analysis
Data were analysed with BMDP statistical software (BMDP Statistical Software, Inc, Los Angeles, CA, USA). Proportions were compared with the χ 2 test or with Fisher's exact test. Mann-Whitney U or Student's t tests were used for comparisons of continuous variables. As all the participants did not answer all the items on the questionnaire, figures in "Results" are given as proportions: number with characteristic/number who answered the question.
RESULTS

All patients
Of the 38 study patients with gastrointestinal symptoms and Y pseudotuberculosis O:3 infection confirmed by stool culture, 33 (87%) returned the questionnaire. The mean age of the responders was 24.7 years (range 2.3-51.6); 18 (55%) were older than 16 years, and 18 (55%) were female. Thirty of 32 (94%) reported abdominal pain (the information was missing for one subject), 24/33 (73%) fever (>37.5°C), and 15/33 (45%) diarrhoea. The median duration of diarrhoea was five days (range 1-38) and the median duration of abdominal pain 14 days .
Thirteen of 33 (39%) subjects had been admitted to hospital because of Y pseudotuberculosis infection, with a median duration of four days (range 2-16). Altogether, 23/33 (70%) subjects had received antimicrobial drugs, mostly fluoroquinolones.
Ocular symptoms were reported by 5/31 (16%), urinary symptoms by 2/31 (6%), and cutaneous symptoms by 5/30 (17%) subjects. Erythema nodosum was seen in one patient.
Patients with ReA
Ten of 33 subjects (30%) reported recent joint symptoms. Of these, four (12%) fulfilled the criteria for ReA and one additional patient had reactive enthesopathy. Thus, a total of 5/33 (15%) patients had reactive musculoskeletal symptoms (table 1). The remaining five subjects had other acute joint symptoms not related to the recent Y pseudotuberculosis infection (such as aggravation of previous joint pain, classical tension neck, and generalised myalgia).
All four patients with ReA were adults, whereas the patient with reactive enthesopathy was a 14 year old boy. Patients with ReA were older (mean 43.1 v 22.2; p=0.03) than those without ReA. The duration of diarrhoea or abdominal pain was not significantly different between patients with or without ReA. Two of four patients with ReA reported urinary symptoms compared with none of 29 patients without ReA (p=0.01).
In all patients with ReA, the arthritis was polyarticular with a median of 24 affected peripheral joints (range 5-27). The median interval between the onset of the first symptoms of infection and joint symptoms was 10 days (range 2-16). The most commonly affected joints were the small joints of the hands and feet, followed by knees, ankles, and shoulders. Besides peripheral arthritis, other musculoskeletal features, such as sacroiliitis (one patient) and heel pain (one patient), were seen. The patient with reactive enthesopathy reported pain in the Achilles tendon and heel pain. HLA-B27 was positive in all three patients with ReA tested.
Three out of four patients with ReA had visited a doctor because of arthritis, and the fourth patient had contacted a local doctor by telephone. The joint symptoms in two of the patients with ReA were sufficiently severe to lead to admission to hospital. In three of four (75%) patients with ReA, the duration of acute arthritis was more than six months. None of the four patients with ReA had a history of previous joint disease.
DISCUSSION
In our study, the incidence of ReA after an outbreak of Y pseudotuberculosis serotype O:3 infection was 12%. Because one additional patient had reactive enthesopathy, some 15% of patients had reactive musculoskeletal symptoms. Although this is slightly less than the 21% in a previous study of an outbreak with Y pseudotuberculosis serotype O:3 infection, 3 it confirms the high frequency of ReA after this infection. Both are higher than the 3% frequency (only one patient) reported after an outbreak of Y pseudotuberculosis serotype O:1a infection. 2 The incidence of ReA appears to be higher in Y pseudotuberculosis serotype O:3 outbreaks than in Y pseudotuberculosis serotype O:1 outbreaks (table 2) . However, as ReA is considered less common in children than in adults, [22] [23] [24] [25] it is possible that the different age distributions in the reported outbreaks might have influenced the observed incidences of ReA. All our four patients with ReA were adults, whereas in the previous study of infection with Y pseudotuberculosis serotype O:3, two of the four patients with ReA were less than 16 years old, 3 and in another study by Tertti et al infection with Y pseudotuberculosis serotype O:1a, the study group comprised only children under 16 years old, and only one child, a 12 year old boy, had ReA. 2 Differences in the occurrence of ReA may be explained by the varying arthritogenic potential of different Y pseudotuberculosis serotypes, differences in case ascertainment, and definitions used for Y pseudotuberculosis infection in the outbreaks, as well as different definitions of ReA (table 2). The limited number of patients in the reported outbreaks may also have a role. In our study ReA was severe in most cases. Three out of four patients had visited a doctor and two of them had been admitted to hospital because of arthritis. In addition, ReA ran a prolonged course (the duration of acute arthritis was more than six months) in three of our four patients. In the previous study of an outbreak of Y pseudotuberculosis serotype O:3, 3 the duration of acute arthritis was not reported. However, in the follow up study of this outbreak 10 years later, two patients with initial ReA had developed ankylosing spondylitis and five patients chronic arthralgia or back pain. 1 In previous reports an occasional duration of acute arthritis for more than six months has also been seen. 5 7 8 11 18 The association between ReA and HLA-B27 is well known. In our four patients with ReA, HLA-B27 was positive in all the three patients tested. In the earlier outbreak of Y pseudotuberculosis serotype O:3, 3 three of the four patients with ReA were HLA-B27 positive.
The arthritis was polyarticular (when each affected joint in fingers and toes was counted individually) with a predominance of small joints of the hands and feet. In one of our patients with ReA, we observed also clinical sacroiliitis as seen previously in occasional cases. 10 14 17 As other musculoskeletal complications, heel pain occurred in two of our patients and Achilles tendinitis in one. Previously, these manifestations have been reported not infrequently in case reports. 10 11 15-18 In conclusion, ReA occurred in 12% of our patients, all adults. The clinical picture of acute arthritis was severe with a prolonged course over six months in the majority of the patients. Y pseudotuberculosis O:3 infection is associated with a high incidence and severe form of ReA. If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to Claire Folkes (cfolkes@bmjgroup.com).
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